NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NeoImmuneTech
NeoImmuneTech
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
University of California, San Diego
Mayo Clinic
National Cancer Institute (NCI)
Boehringer Ingelheim
CHU de Reims
Revolution Medicines, Inc.
Akamis Bio
Universitätsklinikum Hamburg-Eppendorf
Adaptimmune
Novartis
UNC Lineberger Comprehensive Cancer Center
CRISPR Therapeutics
Jemincare
Sanofi
Leiden University Medical Center
University Health Network, Toronto
Centre Hospitalier Universitaire de Saint Etienne
University of California, San Diego
Baptist Health South Florida
Verrica Pharmaceuticals Inc.
Pfizer
Hoffmann-La Roche
National Cancer Centre, Singapore
Universitätsklinikum Hamburg-Eppendorf
Akamis Bio
Akamis Bio
Creative Biosciences (Guangzhou) Co., Ltd.
Laval University
HiberCell, Inc.
Sichuan University
Boston Scientific Corporation
Intensity Therapeutics, Inc.
Sirtex Medical
Vaccinex Inc.
University of California, San Diego
Helsinki University Central Hospital
BeiGene
Columbia University
Changsha Medical University
Imunon
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Federation Francophone de Cancerologie Digestive
Keystone Nano, Inc
Advaxis, Inc.
University Medical Center Groningen
Kyowa Kirin Co., Ltd.
Kyowa Kirin Co., Ltd.